First 4 weeks: 60 mg/m²/day or 2 mg/kg/day PO divided q8hr until urine is protein free for 3 consecutive days; not to exceed 28 days; dose not to exceed 80 mg/day Subsequent 4 weeks: 40 mg/m² or 1-1.5 mg/kg PO every other day; not to exceed 80 mg/day Maintenance in frequent relapses: 0.5-1 mg/kg/dose PO every other day for 3-6 months Treatment may have to be individualized Acne Adrenal suppression Delayed wound healing Diabetes mellitus GI perforation Glucose intolerance Hepatomegaly Hypokalemic alkalosis Increased transaminases Insomnia Menstrual irregularity Myopathy Neuritis Osteoporosis Peptic ulcer Perianal pruritus Pituitary adrenal axis suppression Pseudotumor cerebri (on withdrawal) Psychosis Seizure Ulcerative esophagitis Urticaria Vertigo Weight gain Documented hypersensitivity Systemic fungal infection, varicella, superficial herpes simplex keratitis Receipt of live or attenuated live vaccine; Advisory Committee on Immunization Practices (ACIP) and American Academy of Family Physicians (AAFP) state that administration of live virus vaccines usually is not contraindicated in patients receiving corticosteroid therapy as short-term ( Use with caution in cirrhosis, diabetes, ocular herpes simplex, hypertension, diverticulitis, following myocardial infarction, thyroid disease, seizure disorders, hypothyroidism, myasthenia gravis, hepatic impairment, peptic ulcer disease, osteoporosis, ulcerative colitis, psychotic tendencies, untreated systemic infections, renal insufficiency, pregnancy Thromboembolic disorders or myopathy may occur Delayed wound healing is possible Patients receiving corticosteroids should avoid chickenpox or measles-infected persons if unvaccinated Latent tuberculosis may be reactivated (patients with positive tuberculin test should be monitored) Some suggestion (not fully substantiated) of slightly increased cleft palate risk if corticosteroids are used in pregnancy Parenteral forms (prednisolone sodium phosphate) have been discontinued Suppression of hypothalamic-pituitary-adrenal axis may occur particularly in patients receiving high doses for prolonged periods or in young children; discontinuation of therapy should be done through slow taper Posterior subcapular cataract formation associated with prolonged use of corticosteroids Prolonged use of corticosteroids may increase risk of secondary infections Increase in intraocular pressure associated with prolonged use of corticosteroids Long-term use associated with fluid retention and hypertension Development of Kaposi's sarcoma associated with prolonged corticosteroid use Acute myopathy associated with high dose of corticosteroids Corticosteroid use may cause psychiatric disturbances If product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients; steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be checked frequently Steroids after cataract surgery may delay healing and increase incidence of bleb formation Use of ocular steroids may prolong course and may exacerbate severity of many viral infections of the eye (including herpes simplex) Prednisolone shown to be teratogenic in mice when given in doses 1-10 times human dose; dexamethasone, hydrocortisone, and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation; a significant increase in the incidence of cleft palate observed in fetuses of treated mice; there are no adequate well-controlled studies in pregnant women; prednisolone should be used during pregnancy only if potential benefit justifies potential risk to fetus Not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk; systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects Because of potential for serious adverse reactions in nursing infants from prednisolone, a decision should be made whether to discontinue nursing or to discontinue drug, taking into account importance of drug to mother Glucocorticosteroid; elicits mild mineralocorticoid activity and moderate anti-inflammatory effects; controls or prevents inflammation by controlling rate of protein synthesis, suppressing migration of polymorphonuclear leukocytes (PMNs) and fibroblasts, reversing capillary permeability, and stabilizing lysosomes at cellular level The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. Abimbola Farinde, Pharm D, Ph D Faculty, Columbia Southern University Abimbola Farinde, Pharm D, Ph D is a member of the following medical societies: American College of Clinical Pharmacy, American Academy of HIV Medicine, American Pharmacists Association, Academy of Managed Care Pharmacy Disclosure: Nothing to disclose. Francisco Talavera, Pharm D, Ph D Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Received salary from Medscape for employment. Amoxil 250 mg dosage Zoloft warning signs Table 1. Corticosteroid Dose Equivalents Equivalent Dose Steroid 1. Prednisolone Oral Solution may be given early in the treatment of acute asthma attacks in children. For children over 5 years use a dose of 30-40mg 3-4ml. Those already receiving maintenance steroid tablets should receive 2 mg/kg prednisolone up to a maximum dose of 60mg. The dose of prednisolone may be. Dosing should be individualized based on disease and patient response: Initial dose: 5 to 60 mg orally per day Maintenance dose: Adjust or maintain initial dose until a satisfactory response is obtained; then, gradually in small decrements at appropriate intervals decrease to the lowest dose that maintains an adequate clinical response Comments: -Exogenous corticosteroids suppress adrenocorticoid activity the least when given at the time of maximal activity; consider time of maximal adrenal cortex activity (2 to 8 AM) when dosing. -The delayed-release tablets act similarly to the immediate-release tablets except for the timing of drug release; active drug is released from the delayed-release tablets approximately 4 to 6 hours after intake. -Alternate day therapy may be considered in patients requiring long-term treatment; it may be necessary to return to a full suppressive daily dose in the event of acute flare-ups. Uses: As an anti-inflammatory or immunosuppressive agent when corticosteroid therapy as appropriate, such as for the treatment of certain allergic states; nervous system, neoplastic, or renal conditions; endocrine, rheumatologic, or hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, or gastrointestinal diseases; specific infectious diseases or conditions related to organ transplantation. Dosing should be individualized based on disease and patient response: Initial dose: 5 to 60 mg orally per day Maintenance dose: Adjust or maintain initial dose until a satisfactory response is obtained; then, gradually in small decrements at appropriate intervals decrease to the lowest dose that maintains an adequate clinical response Comments: -Exogenous corticosteroids suppress adrenocorticoid activity the least when given at the time of maximal activity; consider time of maximal adrenal cortex activity (2 to 8 AM) when dosing. -The delayed-release tablets act similarly to the immediate-release tablets except for the timing of drug release; active drug is released from the delayed-release tablets approximately 4 to 6 hours after intake. -Alternate day therapy may be considered in patients requiring long-term treatment; it may be necessary to return to a full suppressive daily dose in the event of acute flare-ups. Erika Giblin, Pharm D Candidate 2015University of Florida, College of Pharmacy Gainesville, Florida Leslie Hendeles, Pharm DProfessor, Pharmacotherapy and Translational Research Professor of Pediatrics (Pulmonary)University of Florida Gainesville, Florida US Pharm. ABSTRACT: Asthma affects approximately one in 10 children in the United States. More than half of these pediatric patients experience an asthma exacerbation each year. Often, the exacerbation requires a short course of oral corticosteroids. Prednisolone, a liquid formulation of prednisone, is commonly prescribed to these children due to its ease of administration. A short course of prednisolone drastically reduces the need for hospitalization and shortens the length of the exacerbation. Poor adherence due to the bitterness or laxative qualities of prednisolone often limits its effectiveness, however, and careful selection must be made between the available forms (prednisolone base versus prednisolone sodium phosphate). Asthma is the most common cause of hospitalizations and emergency department (ED) visits for pediatric patients in the Unites States. Prednisolone dosage chart Pediapred, Orapred prednisolone dosing, indications, interactions., Prednisolone 10mg/ml Oral Solution - Summary of Product. - eMC Buy cialis or viagraSertraline hydrochloride highWhere can i order real viagraMetformin 1000 mg priceWhat viagra does to the body After picking up the prednisolone from the pharmacy, the mother gives her child the prescribed dose of 5 mL. Almost instantaneously, the child. Selecting an Oral Prednisolone Liquid for Children - US Pharmacist. Soluble Prednisolone Tablets 5mg - Summary of Product. - eMC. Prednisone dosing per body weight or body surface area in children.. If you use this medicine for a long time, do not suddenly stop using it without checking first with your doctor. You may need to slowly decrease your dose before. After 2 weeks if no disease progression is noted, the prednisone dose is tapered by 25% per week to 1 mg/kg of prednisone on alternate days. Once the. CLICK ON DOSING CHART TO DOWNLOAD. In pediatric patients, the initial dose of prednisolone sodium phosphate oral solution 25 mg prednisolone per 5.